Puma Biotechnology Inc. (PBYI) announced results from a Phase II clinical trial of PB272, or neratinib, for the treatment of first-line HER2-positive locally recurrent or metastatic breast cancer Friday morning. The treatment did not significantly improve disease-free survival.
Puma Biotechnology gapped open sharply lower Friday, but traded in a range for the bulk of the session. Shares finished with a loss of 23.27 at $216.22. The stock dropped to a 1-month low.
For comments and feedback contact: editorial@rttnews.com
Business News